/
Ophthalmology
Retinitis Pigmentosa
29
Pipeline Programs↗
41
Active Trials↗
21
Companies Involved↗
Retinitis Pigmentosa is an emerging landscape with 29 programs across 21 companies. The most active players are Zhongmou Therapeutics, Novartis, Beacon Therapeutics. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 15
Phase 212
Phase 36
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
14 of 21 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 86% of 29 pipeline programs.
Analysis
Trial Status
97
clinical trials
Completed38 · 39%
Active, not recruiting18 · 19%
Recruiting13 · 13%
Unknown status10 · 10%
Not yet recruiting8 · 8%
Terminated7 · 7%
Other3 · 3%
Clinical Trials
Trial Activity
97 trials
An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT06936787·21 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)